PP-36. Purpura fulminans in newborn case series and report of three rare causative agents in the neonatal period

2010 ◽  
Vol 86 ◽  
pp. S32-S33
Author(s):  
Melek Akar ◽  
Gamze Demirel ◽  
Gonca Sandal ◽  
Omer Erdeve ◽  
Nurdan Uras ◽  
...  
2021 ◽  
pp. 29-30
Author(s):  
Venkatesh B. C. ◽  
Rajendra Rao K. M. ◽  
K. N. Mohan Rao

Corona virus Disease 2019 (COVID-19) pandemic is causing a major health crisis across the globe. With the increasing number of fungal infections associated with COVID-19 being reported, it is imperative to understand the spectrum of such infections. Most documented cases have been reported in patients with diabetes mellitus or treatment with immunomodulators. The most common causative agents are Aspergillus, Candida or Mucorales. This series aims to portray the spectrum of fungal infections associated with COVID-19.


2020 ◽  
Vol 95 (12) ◽  
pp. 1616-1621
Author(s):  
Kyle L. MacQuarrie ◽  
Olatundun Williams ◽  
Kenneth D. Friedman ◽  
Rachel S. Bercovitz

2020 ◽  
Vol 50 (4) ◽  
pp. 330-334
Author(s):  
Sumayya Abdul Kalam ◽  
Ronald AB Carey ◽  
John Antony ◽  
OC Abraham

Acute infectious purpura fulminans is a serious, potentially fatal condition. We present a case series of 11 patients from March 2005 to March 2017, whose clinical symptoms were fever (100%), confusion (63.6%) and headache (55%), and whose common laboratory abnormalities were thrombocytopenia (100%), elevated alkaline phosphatase (70%) and anaemia (63.6%). Three patients (27%) developed gangrene and two presented in shock. Only one grew Neisseria meningitidis in cerebrospinal fluid (CSF) culture and another confirmed by latex agglutination and polymerase chain reaction in CSF. Five others had serology confirmed spotted fever rickettsioses (SFG). All received broad spectrum antibiotics; in 9/11 patients, this included doxycycline or azithromycin. The mean hospital stay was 10.2 days and overall mortality was 18.2%.


Cureus ◽  
2019 ◽  
Author(s):  
Mohammed Asif ◽  
Luis Quiroga ◽  
Tomer Lagziel ◽  
Seth B Ladd ◽  
Julie Caffrey

2016 ◽  
Vol 7 (1) ◽  
pp. 24 ◽  
Author(s):  
Sneha Gandhi ◽  
Saloni Katoch ◽  
Ravindra Kallappa ◽  
MurugeshB Shamanur

2010 ◽  
Vol 95 (Supplement 1) ◽  
pp. Fa51-Fa51
Author(s):  
B. Radhakrishnan ◽  
S. Seshadri ◽  
D. Uchil ◽  
A. Sau ◽  
A. Jolaoso ◽  
...  

2016 ◽  
Vol 44 (12) ◽  
pp. 570-570
Author(s):  
Shashi Raj ◽  
Vasundhara Kailasnath

2021 ◽  
Vol 13 (2) ◽  
pp. 189-196
Author(s):  
Raef Jackson ◽  
Carmen Francis ◽  
Karim Awad ◽  
Semiu E. Folaranmi

We present a case series of two patients with tracheo-oesophageal fistula with oesophageal atresia (TOF/OA), duodenal atresia (DA) and ano-rectal malformation (ARM). This constellation of abnormalities, dubbed triple atresia (TA), is a rare combination with few described cases in the literature. Here we describe our management of these cases, as well as the results of our literature review. Both of our cases had staged surgical procedures and were initially managed with thoracotomy for repair of TOF/OA on day two of life. They subsequently underwent laparotomy for management of their abdominal pathology at day five and seven of life. Both have survived the neonatal period and are awaiting definitive surgery for ARM. Literature review yielded seven cases of TA involving a TOF, DA, and ARM. Four patients underwent staged repair, while three patients underwent repair of TOF/OA, DA and colostomy for ARM at the same time. Of these three patients, two died, representing 22% of the overall cohort. Triple atresia remains a rare subset of patients suspected to have VACTERL association, however mortality may be significantly higher. Our data would suggest a staged approach to be optimal for long term survival.


2020 ◽  
pp. 120347542097234
Author(s):  
Miriam Armanious ◽  
Mohn’d AbuHilal

Background Bullous pemphigoid (BP) is a chronic immune-mediated vesiculobullous disorder. Recently, several reports have described dipeptidyl peptidase-4 inhibitors, also known as gliptins, as causative agents for drug-induced BP. Objective To report and describe clinical and histologic characteristics of 10 cases of gliptin-induced BP. Results We identified 10 patients with gliptin-induced BP. Nine were secondary to linagliptin, and 1 case was attributed to sitagliptin. All patients showed significant improvement after withdrawal of gliptin medications and proper medical treatment. There has been no evidence of relapse after 4 months of follow-up. Conclusion This report supports the proposed association between gliptins and BP. Physicians should be aware of this potential adverse effect, as gliptin-induced BP can be reversible once identified and the responsible medication is stopped. Early withdrawal of the offending drug and proper treatment can lead to rapid improvement and reduced morbidity.


Sign in / Sign up

Export Citation Format

Share Document